Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Associations between purine metabolites and clinical symptoms in schizophrenia

Yao, JK and Condray, R and Dougherty, GG and Keshavan, MS and Montrose, DM and Matson, WR and McEvoy, J and Kaddurah-Daouk, R and Reddy, RD (2012) Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS ONE, 7 (8).

Published Version
Available under License : See the attached license file.

Download (365kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: The antioxidant defense system, which is known to be dysregulated in schizophrenia, is closely linked to the dynamics of purine pathway. Thus, alterations in the homeostatic balance in the purine pathway may be involved in the pathophysiology of schizophrenia. Methodology/Principal Findings: Breakdown products in purine pathway were measured using high-pressure liquid chromatography coupled with a coulometric multi-electrode array system for 25 first-episode neuroleptic-naïve patients with schizophrenia at baseline and at 4-weeks following initiation of treatment with antipsychotic medication. Associations between these metabolites and clinical and neurological symptoms were examined at both time points. The ratio of uric acid and guanine measured at baseline predicted clinical improvement following four weeks of treatment with antipsychotic medication. Baseline levels of purine metabolites also predicted clinical and neurological symtpoms recorded at baseline; level of guanosine was associated with degree of clinical thought disturbance, and the ratio of xanthosine to guanosine at baseline predicted degree of impairment in the repetition and sequencing of actions. Conclusions/Significance: Findings suggest an association between optimal levels of purine byproducts and dynamics in clinical symptoms and adjustment, as well as in the integrity of sensory and motor processing. Taken together, alterations in purine catabolism may have clinical relevance in schizophrenia pathology.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Yao, JKjkyao@pitt.eduJKYAO
Condray, R
Dougherty, GGggd@pitt.eduGGD
Keshavan, MSkeshavan@pitt.eduKESHAVAN
Montrose, DM
Matson, WR
McEvoy, J
Kaddurah-Daouk, R
Reddy, RDravir@pitt.eduRAVIR
ContributionContributors NameEmailPitt UsernameORCID
Date: 14 August 2012
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 7
Number: 8
DOI or Unique Handle: 10.1371/journal.pone.0042165
Schools and Programs: School of Medicine > Psychiatry
School of Pharmacy > Pharmaceutical Sciences
Refereed: Yes
Other ID: NLM PMC3419238
PubMed Central ID: PMC3419238
PubMed ID: 22916123
Date Deposited: 18 Oct 2012 20:53
Last Modified: 02 Feb 2019 15:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item